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This paper deals with characterization of liposomal formulations with encapsulated 
triethylenetetramine (TETA), which is selective CuII- chelator used in the treatment of 
Wilson's disease for decades. Liposomal formulations were prepared by a film 
hydration method with subsequent dual asymmetric centrifugation with the addition 
of 2.5 mol/l TETA solution dissolved at pH3 or/and pH7, respectively. Size exclusion 
chromatography (SEC) was performed to separate free-TETA from the encapsulated-
one at day 1, 2, 3, 4, 5 and 8. Two methods of liposome purification, the one column 
method and the two columns method, were used. The size and the size distribution of 
prepared liposomes were measured by photon correlation spectroscopy (PCS) at each 
day of storage. The concentration of encapsulated TETA, as well as the concentrations 
of cholesterol before the SEC and after the SEC were determined by HPLC in order to 
express the encapsulation efficiency. No influence of pH or the method of purification 
on the liposome stability (the average size) were found. However, the higher 
polydispersity was observed for TETA-liposomes with pH7 purified by the two 
columns method. The pH value and/or the method of purification significantly 
influenced the variability of the obtained data or/and the encapsulation efficiency (EE), 
respectively. The more consistent results of EE during the days of storage were 
observed with the dissolution of TETA at pH3 value; the higher EE was obtained for 
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Táto práca sa zaoberá charakterizáciou lipozomálnych formulácii s enkapsulovaným 
triethylentetraamínom, ktorý sa používa ako selektívny CuII- chelátor k liečbe 
Wilsonovej choroby už po desaťročia. Liposomálne formulácie boli pripravené 
filmovou metódou s následnou duálnou asymetrickou centrifugáciou s prídavkom 2.5 
mol/l triethylentetraamínu rozpusteného jednotlivo v pH3 alebo/a pH7. Bola 
prevedená gélová chromatografia za účelom separácie voľného triethylentetramínu od 
enkapsulovaného v deň 1, 2, 3, 4, 5 a 8. Boli použité dve metódy čistenia: 
jednokolonková a dvojkolonková. Veľkosť a distribúcia veľkosti častíc bola určená 
pomocou fotón korelačnej spektroskopie. Pomocou HPLC bola určená koncentrácia 
enkapsulovanej TETY, rovnako ako aj koncentrácie cholesterolu pred a po gélovej 
chromatografii za účelom vyjadrenia enkapsulačnej účinnosti. Nebol zistený vplyv 
hodnoty pH, ani metódy čistenia na stabilitu lipozómov (priemernú veľkosť). Avšak, 
vyššia polydisperzita bola pozorovaná pre TETA-lipozómy s pH7 čistené 
dvojkolonkovou metódou. Hodnota pH alebo/a metóda čistenia významne ovplyvnili 
variabilitu získaných výsledkov a/alebo enkapsulačnú účinnosť. Boli pozorované 
konzistentnejšie výsledky enkapsulačnej účinnosti pre triethylentetramín rozpustený 




3 The aim of study 
As the theoretical background of this work, liposomes, its classification, materials used 
for preparing of liposomes, preparation techniques including dual asymmetric 
centrifugation, the principle of size exclusion chromatography and photon correlation 
spectroscopy, the drug triethylenetetramine and its uses will be described. 
The purpose of this thesis is to prepare liposomes with triethylenetetramine (TETA) 
dissolved at pH3 or/and pH7 by a film hydration method followed by a dual 
asymmetric centrifugation. Photon correlation spectroscopy is used to evaluate the 
stability of prepared liposomes, i.e. their size and polydispersity.  
The concentration of encapsulated TETA and the concentrations of cholesterol before 
the size exclusion chromatography (SEC) and after the SEC are determined by HPLC 
in order to calculate the encapsulation efficiency of TETA in liposomes. 
The influence of the method of purification and the value of pH used on the properties 




4 List of abbreviations 
BBB  Blood-brain barrier 
Conc (mM) Concentration 
d (nm) diameter 
D (m2·s-1) translational diffusion coefficient 
DAC  Dual asymmetric centrifugation 
DAT  N1, N10-
diacetyltriethylenetetramine 
d (H) (m) hydrodynamic radius 
EE (%) Encapsulation efficiency 
EPC  Egg-phosphatidylcholine 
Fig  Figure 
FMOC  9-flouorenylmethylchloroformate 
GUV  Giant unilamellar vesicles  
GM1  Monosialoganglioside 
HPLC  High performance liquid 
chromatography 
Chol  Cholesterol 
k   (1.38·10-23 J·K-1) Boltzmann’s constant 
LUV  Large unilamellar vesicles 
LMV  Large, multilamellar vesicles 
MAT  N1-acetyltriethylenetetramine 
MLV  Multilamellar vesicles 
ŋ  (N·s·m-2) viscosity of suspending liquid 
OLV  Oligolamellar vesicles 
PBS  Phospate Buffered Saline 
PCS  Photon correlation spectroscopy  
PdI  Polydispersity index 
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PEG- PE  Polyethylene glycol modified with 
polyethanolamine 
PLs  Phospholipids 
P1  Purification 1 
P2  Purification 2 
SEC  Size exclusion chromatography 
SD  Standard deviation 
S1  Sample 1 
S2  Sample 2 
SUV  Small unilamellar vesicles 
T (K) Absolute temperature 
TETA  Triethylenetetramine 
WD  Wilson disease 






Development of drug delivery systems for brain-targeting represents one of the most 
challenging research topics in the pharmaceutical field, mainly due to the presence of 
the blood-brain barrier (BBB), which separates the blood from the cerebral 
parenchyma thus limiting the brain uptake of the majority of drugs. Among the several 
carriers, which have been developed to overcome this problem, liposomes have 
attracted significant attention as promising agents for brain-targeted drug delivery.1 
Triethylenetetramine (TETA) is drug commonly used for the treatment of Wilson's 
disease, which is manifested by copper accumulation in tissues, brain including. 
Although TETA has been used for decades, there is just one medical product on the 
market: Capsules SYPRINE and pharmacologic or clinical information are very 
limited or unavailable.2 
This thesis aims to investigate and determine the size, size distribution and 
encapsulation efficiency of TETA (dissolved at pH3 or/and pH7) in liposomes 
prepared from cholesterol (chol), egg-phospatidylcholine (EPC) and polyethylene 
glycol modified phospatidyl ethanolamine (PEG-PE). It was already determined that 
PEG-PE extends circulation lifetimes when incorporated into liposomes.3  
The following techniques were used for this project: 
 Liposome production and formation by the film hydration method 
 Dual asymmetric centrifugation 
 Size-exclusion chromatography 
 Photon correlation spectroscopy 




6 Theoretical section 
6.1 Liposomes 
The word liposome comes from two Greek words: ‘Lipos’ meaning fat and ‘Soma’ 
meaning body. Since their discovery in mid-60s, the field of liposome research has 
progressed enormously, increasing applications area from drug and gene delivery to 
cosmetics, diagnostics or food and chemical industry.4 They were first described by 
British haematologist Bangham at the Babraham Institute in Cambridge as a model of 
cellular membranes. According to legend, Bangham and his colleague were testing the 
institute's new electron microscope, when they made a noted observation about 
phospholipids forming closed multilamellar vesicle spontaneously in an aqueous 
solution.5 
Liposomes are sphere-shaped nanovesicles consisting of a central aqueous 
compartment surrounded by one or more membraneous lipid bilayers. Membranes are 
usually made of phospholipids, which are molecules with a hydrophilic head group 
and a hydrophobic tail group, which is made of a long hydrocarbon chain. In the 
presence of water, the head is attracted to water and the tail is repelled by water.5 
Furthermore, the choice of bilayer components estimates the ‘fluidity’ and the charge 
of the bilayer. For example, unsaturated phosphatidylcholine species from natural 
sources (for instance, egg phosphatidylcholine) help create much more permeable and 
less stable bilayers, whereas the saturated phospholipids with long acyl chains 
(dipalmitoylphosphatidylcholine) form a rigid, impermeable bilayer structure.6 
Phospolipids impulsively create closed structure when are hydrated in aqueous 
solution. Because of liposomes unique structure, hydrophilic, hydrophobic and 
amphiphilic substances may be incorporated within these vesicles. Hydrophilic 
molecules are encapsulated in the interior aqueous compartments, while liphophilic 
drugs can be accommodated in the lipid phase.4, 5 The surface of liposomes can be 






Fig. 1. Schematic illustration of liposome structure and liphophilic and hydrophilic drug 
entrapment models4 
Liposomes are used as drug delivery systems due to their excellent characteristics like 
biodegradability, biocompatibility, flexibility, increasing therapeutic index of drug and 
efficacy, increasing stability of entrapped drug from hospital environment, reducing 
side effects, providing sustained release and acting as reservoir of drug.8 
They can be formulated and processed to differ in size, composition, lamellarity and 
charge and can be administered by many routes e.g. oral, nasal, pulmonary, 
intravenous, intramuscular, topical, and ocular.8, 9 
6.1.1 Classification of Liposomes 
Liposomes can be classified on the basis of various characteristics, such as size, 






Fig. 2. Classification of liposomes7 
6.1.1.1 Classification based on size and lamellarity 
Liposomes are most commonly classified by their size and the number of lipid bilayers. 
Unilamellar vesicles have a single phospholipid bilayer sphere enclosing aqueous 
solution and are divided into three size types:7 
 small unilamellar vesicles (SUV): 20–100 nm 
 large unilamellar vesicles (LUV): > 100 nm 
 giant unilamellar vesicles (GUV): > 1000 nm 
Oligolamellar vesicles (OLV), 100–500 nm, are rare, although an example of a 





Multilamellar vesicles (MLV), > 500 nm, have onion structure which form one inside 
the other, creating a multilamellar structure of concentric phospholipid spheres 
separated by layers of aqueous solution.4, 9, 10 
 
Fig. 3. Liposomes classification based on size and lamellarity4 
The size of liposomes plays a significant role in their clearance—the extent of its 
importance varies for conventional and sterically stabilised (“stealth”) liposomes. 
Strong size dependence can be found in clearance of conventional liposomes following 
i.v. administration; as the liposome diameter increases the rate at which the liposomes 
are eliminated from blood into the reticuloendothelial system also increases.7 
In case of sterically stabilised liposomes with average size around 250.0 nm, it was 
observed that they are slowly filtered out by liver Kupffer cells. At size above 300 nm, 
increased uptake into the spleen occurs, apparently by a mechanism of passive 
filtration.7  
6.1.1.2 Classification based based on circulation in vivo 
The conventional liposomes are typically composed of neutral phospholipids like 
phosphatidylcholine along with varying amounts of cholesterol and sometimes small 
amount of an acidic phospholipid. Cholesterol is important for increasing the stability 
of liposomes in the presence of plasma, and the negative charge is added to avoid 
aggregation and to increase encapsulation efficiency. These liposomes are cleared 
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from the blood stream rapidly thanks to phagocytic cells of the reticuloendothelial 
system. Their half-life decreases with increasing diameter, negative charge and 
fluidity.7  
Within last decades, many experiments have been performed to improve plasma 
stability of liposomes by the addition of specific mixtures to their surface. These so-
called sterically stabilised liposomes extend circulation time in blood due to a reduced 
recognition rate by cells and macrophages. Most of the initial studies were made with 
monosialoganglioside (GM1) or phosphatidyl inositol as a stabilising component. Best 
results were achieved by modifying the liposomal surface with hydrophilic polymers 
like polyethylene glycol.3, 11 The effect of glycolipids and polysaccharides on liposome 
circulation time was investigated after consideration of the structure of the red cell 
outer membrane, which surface consists of glycolipids and sialic acid.12 
6.1.1.3 Classification based based on surface charge 
The charge of classic liposomes is originally neutral, therefore charge inducers are 
used for modification of the net surface charge of liposomal formulation. Stearylamine 
can be used as a cationic charge inducer, while diacetylphospate or phosphatidyl serine 
to prepare the negatively charged liposomes.9 These charged liposomes are removed 
more rapidly than the classical ones. The splenic uptake is typical for the negative 
charged liposomes and is about twice faster than for the positively charged ones. 
Liposomes with positive surface charge are playing a significant role in recombinant 
DNA-technology and are also called as liposomal DNA delivery vectors.7  
6.1.1.4 Classification based based on clinical applications 
Applications of liposomes in medicine and pharmacy can be divided according to the 
therapeutic and diagnostic purpose.  
 
Diagnostic application 
Large liposomes are removed quickly via uptake by the reticuloendothelial system of 
the liver and spleen. This fact can be used in passively targeting for delivering 
diagnostic imaging agents into these organs.7 The ability of liposomes to carry 
different compounds make them suitable for all contrast procedures such as 
12 
 
sonography, gamma scintigraphy, magnetic resonance imaging or computed 
tomography imaging.8  
 
Therapeutic application 
Liposomes have shown tremendous therapeutic potential as drug carriers. However, 
the benefits and limitations of liposome depend on the interaction of liposomes with 
cells and their faith in vivo after administration. Studies of these interactions between 
liposomes and cells have shown that there are four possible mechanisms of adsorption: 
simple adsorption, subsequent endocytosis, fusion, which is rare or exchange of bilayer 
components.13 
Liposomes can offer several advantages over conventional dosage forms especially for 
parenteral, topical and pulmonary route of administration. The possibility of 
modulating the technological characteristics of the vesicles makes them highly 
versatile both as carriers of different kinds of drugs (from conventional 
chemotherapeutics to proteins) and in therapeutic application (from vaccination to 
cancer therapy). In previous years, several important formulation for the treatment of 
different disease have been developed or are currently undergoing clinical trials. 
Doxorubicin, daunorubicin, amphotericin B or vincristine can be mentioned as an 
example of the most successful encapsulated drugs in the liposomal formulation.4,13 
6.2 Material used for liposome preparation 
Liposomes can be formed from a variety of lipids and their mixtures. 
6.2.1 Phospholipids 
Phospolipids (PLs) can be found in high proportions in cell membranes of living 
matter. PLs are amphipathic molecules consisting of two fatty acids linked to a polar 
head group and as the back bone glycerol or sphingomyeline is used. The two 
hydrocarbon chains constitute the hydrophobic tails, while the phosphate group and its 
polar attachment constitute the hydrophilic tail. PLs can consist of different head and 
tail groups that affect the surface charge and bilayer permeability of the liposomes. 
Phospatidyl ethanolamine, phospatidyl glycerol, phospatidyl serine, 
phosphatidylinositol and phospatidylcholine (see Fig 4.) belong to most common used 
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glycerophospholipids. Phosphatidylcholine can be derived from natural or synthetic 
sources.14 
 
Fig. 4. Structure of EPC molecule15 
The packing of the hydrocarbon chains of lipid molecules influences the stability of 
the liposome. The membrane transforms from a fully extended and closely packed “gel 
phase” to a liquid crystalline disordered at the main transition temperature, which is 
dependent on the hydrocarbon chain length and degree of saturation of the acyl chains. 
In general, rigid bilayers are less permeable to solutes than fluid membranes.16 
6.2.2 Cholesterol  
Cholesterol (Fig 5) does not form a bilayer on its own, but can be incorporated into the 
lipid bilayers at concentrations up to 1:1 molar ratio. Due to its amphiphatic properties, 
chol itself inserts in the bilayer with its OH-groups oriented towards the aqueous core 
and the rigid hydrophobic tail toward the bilayers. The presence of chol in the lipid 
bilayer increases the stability and form highly ordered and rigid membrane with fluid 
like characteristics.17 
 




6.2.3 Polyethylene glycol 
As mentioned above, sterically stabilized liposomes in which the surface has been 
altered offer significant advantages over conventional liposomes. The resulting 
liposomes are more hydrophilic and less able to bind opsonins from plasma.  
 
Fig. 6. Structure of 1, 2- distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000] (ammonium salt) (PEG- 2000PE)19 
One solution how to achieve this goal is to use polyethylene glycol, which can be 
incorporated in different ways: by the physical adsorption of the polymer onto the 
surface of liposomes, by incorporation of PEG-lipid conjugate during liposome 
preparation, or by covalent attachment of reactive groups onto the surface of 
performed liposomes.12 Coating of liposomes with polyethylene glycol (PEG) further 
allows a prolonged circulation time in plasma allowing prolonged dosing intervals.20 
6.3 Preparation techniques of liposomes 
The following parameters are important for the correct choice of liposome preparation 
method:5 
1. The physicochemical characteristics of the substance to be entrapped and those 
of the liposomal mixtures 
2. The nature of the medium in which the lipid vesicles are mixed 
3. The concentration of entrapped substance and its potential toxicity 
4. Additional processes involved during application 
5. Size, polydispersity and shelf-life of the vesicles 




6.3.1 Mechanical methods 
Method of film lipid hydration 
The origin of this method was developed by Bangham21 and still remains the simplest 
procedure for liposome preparation, however having some difficulties thanks to its low 
encapsulation efficiency.  
Liposomes are prepared by hydrating the thin lipid film in an organic solvent following 
with the remove of the solvent to yield a lipid film. A dry nitrogen or argon steam in 
fume hood are used to evaporate of small volumes of organic solvent; for larger 
volumes, the solvent can be eliminated by rotary evaporation, where thin lipid film is 
formed on the sides of round bottom flask. To remove the residual organic solvent, the 
vial or flask is placed for 1 hour in the exsiccator under vacuum.5 
When all the solvent is removed, the lipid film is hydrated using aqueous medium. 
Hydration time may differ slightly among lipid structure and composition of a mixture. 
It is recommended to use hydration time around 1 hour with additional mixing, shaking 
or stirring. The lipids swell and hydrate forming a heterogenous sized population of 
large, multilamellar vesicles (LMV).5, 22 For converting MLV suspension to liposomes 
of smaller size, the extrusion, sonication or French pressure cell method can be used.8  
Sonication method 
This method is used for preparation of SUVs from MLVs prepared by the conventional 
method. The sonication is based on pulsed, high frequency sound waves (sonic 
energy), which agitate a suspension of MLV. Suspension is sonicated either with a 
bath type sonicator which is more suitable for a large volume of a sample or a probe 
sonicator recommended for the small volume of a sample.23 
French pressure cell method 
This method was originally developed for disrupting cells under better conditions 
compared to the ultrasound method, because lipid, as well as proteins or other sensitive 
compounds might be degraded during the sonication. This method involves the 
extrusion of MLVs at 20, 000 Pa at 4 °C through a small orifice, however system can 
be used only in the volume of 1–40 ml.24 
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6.3.2 Methods based on replacement of organic solvent 
Generally, lipids are dissolved in organic solvents, which is then dispersed into 
aqueous medium containing substance to be entrapped.22  
Ether infusion method 
A solution of lipids dissolved in diethylether or ether-methanol mixture is carefully 
injected to an aqueous solution of the substance to be encapsulated at 55 to 65 °C. The 
following removal of ether under vacuum leads to formation of liposomes. 
Disadvantages of this method include the exposure of compounds to be encapsulated 
to the organic solvent, the use of high temperature and the preparation of liposome 
formulation having large size distribution (70–190nm).8  
Ethanol Injection method 
An ethanolic solution of lipids is injected to a vast excess of a buffer. As a result, the 
MLVs are formed. The main disadvantage of this method is heterogeneous population 
of liposomes (30–110nm).9  
Reverse phase evaporation technique 
First, the water-in-oil emulsion is shaped by brief sonication of a two-phase system 
containing phospholipids in an organic solvent and an aqueous buffer. The organic 
solvents are removed under reduced pressure by a rotary evaporator, resulting in the 
formation of a semi-solid gel. Liposomes are formed when residual solvent is 
eliminated by continued evaporation. In a medium of low ionic strength, a high 
encapsulation efficiency up to 65 % can be achieved. The main drawback is the 
exposure of the material to be encapsulated to organic solvents and to brief periods of 
sonication.25 
6.3.3 Other methods 
High pressure extrusion method 
This method is widely used process for converting MLVs to SUVs suspensions, in 
which liposomes prepared by conventional method are repeatedly forced under high 
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pressure through polycarbonate membrane filters with the defined pore size. The 
mechanism of action appears to be like peeling onion.23  
Dual asymmetric centrifugation 
Dual asymmetric centrifugation (DAC) is a special kind of centrifugation. While in 
conventional centrifugation, vials turn around the main rotation axis at defined 
distance and speed, vials in the DAC process turn around their own centre as well as 
around the centre of centrifuge similarly to the normal centrifugation process. This 
result in two overlying movements of the sample material in the centrifugation vial. 
The main rotation pushes the sample material in an outward direction in response to 
centrifugal forces, while the additional rotation of the centrifugation vial around its 
own centre constantly pushes the sample material in the opposite direction due to 
adhesion between the sample material and the rotating vial (see Fig. 7, Fig 8).26 
 
Fig. 7. Schematic illustration of DAC principle26 
If sufficient adhesion of the sample material on the vial material is presented and the 
sample material is viscous enough, the latter movement, the inward transport of the 
sample material, is effective. Both of these factors can affect the transference of energy 
into the sample material. Therefore, DAC is suitable for homogenization of the viscous 
material. The product of homogenization is vesicular phospholid gel, which can be 




It was already shown, that the DAC speed, the homogenization time, the lipid 
concentration and the addition of glass beads are the critical factors for the liposomes 
size.26 
The optimal lipid concentration in range from 350 up to 450 mg/ml, the 
homogenization time of 30 minutes or longer at maximum speed 3540 and the addition 
of 50 up to 125 weight percent of glass beads (related to total mass of lipid dispersion) 
result in the desired small liposomes in a highly reproducible manner.26  
 
Fig. 8. Dual asymmetric centrifugation, A- DAC with open lid, B- view into the rotation 
chamber26 
6.3.4 Drug loading into liposomes 
Drug loading can be achieved either passively, which means that drug is encapsulated 
during the liposome formation, or actively, after the liposome formation. Hydrophobic 
drugs like amphotericin B or taxol, can be incorporated into liposomes during their 
formation, and the range of uptake and retention is managed by drug-lipid interactions. 
The trapping efficiency is dependent on the solubility of the drug in the liposome 
membrane. The passive encapsulation of hydrophilic drugs depend on the ability of 
liposomes to trap the aqueous medium containing a dissolved drug during the liposome 
formation. The trapping efficiency is limited by the trapped volume contained in the 




6.4 Methods used for purification and characterization of 
liposomes 
6.4.1 Size exclusion chromatography  
In order to determine encapsulation efficiency of a drug and/or the amount of a drug 
incorporated within liposomes over time, the external drug in the outer aqueous phase 
of the liposome dispersion must be removed. One of the most suitable method for this 
is size exclusion chromatography (gel filtration chromatography).28 
Gel filtration, or size exclusion chromatography, is a simple chromatography 
technique, separating molecules according to difference in size as they pass through a 
gel filtration medium packed in a column. It is based on the fact that in a gel, 
sufficiently small species (such as ions or drug) have the tendency to enter the pores 
of gel particles while bigger molecules such as liposomes, may not be able to enter 
into the pores of the gel at all, see Fig 9. When not entering the pores, the large 
molecules and particles instead move through the column at the same speed as the 
aqueous medium used for elution of the column.29 
 
Fig. 9. Description on how SEC works30 
Sephadex is a gel made from cross-linked dextran with. Different type of sephadex gel 
vary in degree of cross linking, and hence in their degree of swelling, and their 
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selectivity for the molecules of different sizes. The sephadex gels have names that start 
whit a G (i.e. gel), and ends with a number. For example, in Sephadex G-50 “50” 
stands for the water regain of the gel, in the instance of G-50, 5.0 g water per g dry 
gel. Sephadex G-50 is suitable for separating large molecules, relative molecular 
weight (Mr) >30 000, from molecules with Mr under 1 500 mg/ml. That makes it 
suitable for separating liposomes from a substance in the outer phase.29 
6.4.2 Photon correlation spectroscopy 
There are two methods for determining the size of liposomes: the electron microscopic 
examination and Dynamic Light Scattering, sometimes referred as Photon Correlation 
Spectroscopy (PCS) or Quasi-Elastic Light Scattering.  
Electron microscopy is considered as one of the most precise method, because it 
permits to view each individual liposome and enables to obtain accurate information 
about the profile of a liposome population over the whole range of sizes. However, 
this technique can be very time-consuming and requires equipment that may not be 
immediately at hand.31 In contrast, PCS is simple, automatized and rapid to perform.  
PCS measures the Brownian motion of particles, which is a random movement of 
microscopic particles suspended in liquid caused by collisions with molecules of the 
surrounding medium. Shining a monochromatic light beam, such as a laser, onto a 
suspension with particles in this motion causes a Doppler Shift when the light hits the 
moving particles, changing the wavelength of the light source. Then, it is possible to 
calculate the size distribution and give a description of the particles motion in the 
suspending liquid, measuring the diffusion coefficient of the particle and using the 
autocorrelation function.31 
This dimension is usually expressed as translational diffusion coefficient, signed as the 






         (1) 
 
Where: 
d (H) = hydrodynamic radius (m) 
k = Boltzmann’s constant (1.38·10-23 J·K-1) 
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T = absolute temperature (K) 
ŋ = viscosity of suspending liquid (N·s·m-2) 
D = translational diffusion coefficient (m2·s-1) 
 
It is necessary to keep a constant temperature during the measurement, because the 
viscosity is strongly temperature-dependent. The translational diffusion coefficient is 
dependent on the size of particle “core”, on the surface structure of the particle and on 
the concentration and type of ions in medium.32, 33 
A typical PCS instrument consists of six main components Fig 10. Laser (1) provides 
the light source for illuminating the sample particles within a cell (2). The scattered 
light is measured by the detector (3), which is positioned at 173° or 90° (according to 
different kind of instrument). The intensity of scattered light must be within a certain 
range, otherwise the detector is not able to measure it correctly. The intensity of the 
laser source and the intensity of scattering are regulated by attenuator (4). The 
scattering intensity signal is then passed to a correlator, which compares the scattering 
intensity at successive time intervals to derive it the rate at which intensity is varying. 
Data from correlator are sent to the computer (6). Special software analyses these data 
and calculates the size of particles in the sample.34  





Fig. 10. Main components of Zetasizer Nano ZS34 
6.5 Wilson’s disease and triethylenetetramine  
Triethylenetetramine (TETA) is an established orphan drug commonly used for the 
treatment of Wilson’s disease (WD). 35 Wilson’s disease is an autosomal recessive 
inherited disorder caused by abnormal cooper metabolism and is also lethal if left 
without diagnosis and prompt treatment. Illness is manifested by cooper accumulation 
in many organs of patient, mainly the liver, cornea and brain. Depending on what parts 
are affected, illness presents as various psychiatric or neurologic symptoms and 
hepatic dysfunction (acute or chronic hepatitis, cirrhosis, the Kayser-Fleischer ring, 
cardiomyopathy, Parkinson-like symptoms, etc). Treatment is focused on achieving a 
negative cooper balance either with chelators, currently available drugs include D-
Penicillamine, TETA and Ammonium tetrathiomolybdate, or Zinc which helps 
prevent cooper absorption from intestinal tract or both.36, 37 
TETA is CuII- selective chelator, with promising clinical applications and 
implications. It has been used as the second line treatment for patients with WD, who 
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developed toxic reactions to penicillamine. TETA increases urinary Cu excretion and 
also decreases intestinal cooper absorption. TETA is poorly absorbed with relatively 
low bioavailability (from 8 % to 30 %) and is widely distributed into different tissues 
with higher concentration measured in liver, kidney and heart. Two metabolites of 
TETA have been identified in human plasma and urine, being N1-
acetyltriethylenetetramine (MAT) and N1, N10-diacetyltriethylenetetramine (DAT). 
Although TETA has been used in treatment for decades, information about its 
pharmacology is still limited and any comprehensive review does not exist to this 
date.35, 38 
However, it has been suggested, that TETA may be a promising anticancer agent 
because it inhibits telomerase and has anti-angiogenesis properties.39, 40 TETA has also 
been used in clinical trials for the treatment of diabetic heart failure and has shown to 
be effective in patients with diabetes type 2 presenting cardiac complication.41 
6.5.1 Detection of TETA 
TETA is a synthetic analog of polyamine compounds spermidine and spermine 
(Fig. 11) and with four nitrogen groups acts as a perfect CuII- selective chelator. 
TETA itself has a very polar structure, does not elute efficiently from HPLC column 
and possesses no UV-VIS absorption or emits fluorescence. Thus for its analysis using 
high performance liquid chromatography (HPLC) with conventional UV or 
fluorescence detectors, the drug has to be derivatized with a suitable reagent.35 
Derivatization is a chemical process that leads to new products with improved 
chromatographic properties and can be done prior to the separation step 
(prederivatization) or as a postcolumn derivatization.42 Recently, the reaction with the 
derivatizing agent 9-fluorenylmethyl chloroformate (FMOC-Cl) has shown to be as 
the most suitable precolumn derivatizing method. In this process, substitution of four 
hydrogen atoms in the amino group occurs in the TETA molecule by aromatic rings 
containing alternating double bonds, Fig. 12. The main advantage of using FMOC, is 
in its capability to label not only TETA, but also its two major metabolites. Any other 
to this date published quantification procedure is not capable of simultaneous 






Fig. 11. Structure of polyamines, TETA and TETA-CuII complex35 
 






7 Experimental section 
7.1 Chemicals 




2000] (ammonium salt) (PEG-2000-
PE) 
Avanti Polar Lipids, Inc. >99 % 
9-Fluorenylmethylchloroformate 
chloride 
Sigma-Aldrich Chemie GmbH 97 % 
Acetonitrile Sigma-Aldrich Chemie GmbH >99 % 
Chloroform central supply of Univeristy ≥ 99 % 
Cholesterol Cholesterol Sigma-Aldrich 
Chemie GmbH 
≥ 99 % 
Dubbeco's Phospate Buffered Saline 
(DPBS) 
Gibco® by life technologies n.a. 
Egg-phosphatidylcholine Lipoid GmbH ~80 % 
Ethanol central supply of University 99 % 
Isopropanol central supply of University 99,9 % 
Methanol VWR International GmbH 99,8 % 
Triethylentetramin Monohydrat 
(TETA) 
Sigma-Aldrich Chemie GmbH 98 % 
Trifluoroacetic acid Merck KGaA ≥ 98 % 





Buffers and solutions 
Name Ingredients Concentration 
Borax ph9 NaOH 
H3BO3 
10 M 










7.2 Instruments and materials 
Designation Details Producer 
Eppendorf tubes 1.5 ml, 2 ml Eppendorf, Hamburg, 
Germany 
Glass beads ø 0,75-1 mm Roth GmbH & Co. KG 
HPLC-Column Acclaim® 120, c18 5µm, 
120 Å, 4,6 x 250 mm 
Dionex Corporation 
HPLC-Column Luna 3μ C18 150 × 3.0-
mm 
Phenomenex 
Plastic cuvettes Rotilabo® , PS  Roth GmbH & Co. KG 
Polyethylen frits ø 0,5 & 2 cm  Sigma-Aldrich Chemie 
GmbH  
Sephadex  G-50 Fine GE Healthcare GmbH 
Speedmixer DAC 150 FVZ Hauschild Engineering 
GmBH 
Ultimate 3000 HPLC device Dionex Corporation 
Zetasizer Nano ZS Particle Analyser Malvern Instruments Ltd 
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7.3 Methods used in formulation and evaluation of liposomes 
7.3.1 Production of liposomes by film method 
For preparing liposomes, egg-phosphatidylcholine (EPC), cholesterol and 1, 2- 
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-
2000] (ammonium salt), (PEG-2000-PE) were used. 
I prepared stock solution of each lipid in the volume of 10 ml in advance. Each lipid 
was separately dissolved in solvent mixture of chloroform and methanol (9:1) to 
achieve the desired concentration as shown in Tab. 1.  





EPC 760 100 
Cholesterol 386.7 100 
PEG-2000-PE 2805.5 10 
 
Using the stock solutions, I prepared the mixture of lipids in the 2 ml eppendorf tube 
containing 55 % of EPC, 40 % of Chol and 5 % of PEG-2000-PE calculated for the 
final volume of liposomal solution with TETA after dual asymmetric centrifugation 
(DAC), which was 400 µl as shown in Tab. 2.  
Tab. 2. Parameters of the lipid mixture 







EPC 55 220 16.72 
Chol 40 160 6.18 
PEG-2000-PE 5 200 5.61 
 
Eppendorf tubes were positioned into the water bath at 50° C and the tip of nitrogen 
stream was placed near the liquid level. The solvent was vaporized in the range of 10 
to 15 minutes. After evaporation of the organic solvent a lipid film was created on the 
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wall of the tube. For removing residual solvent, the film lipid was positioned under the 
vacuum in the desiccator for one hour. 
7.3.2 Passive loading of triethylenetetramine into liposomes 
The method of dual asymmetric centrifugation (DAC) was used for the encapsulation 
of TETA into liposomes. 
Triethylenetetramine Monohydrat (Mw -146.23 g/mol) was dissolved in 5 ml 
volumetric flask in Phospate Buffered Saline (PBS) and/or in a buffer solution pH3, 
respectively, to achieve the concentration of 2.5 mol/l.  
The mass of the dried lipid film was calculated and an equal amount of glass beads (ø 
0.75–1 mm) was added. I added the solution of TETA in buffer (PBS and/or pH3). 
Then, the mixture was subjected in three steps to dual asymmetric centrifugation 
(DAC) according to the schedule described in Tab. 3.  
In the first step, the 1.5fold of the mass of dried lipid film (43 l) of 2.5 mol/l TETA 
solution in the buffer solution pH3 and/or in PBS, respectively, was added and 
centrifuged for 30 min at 3540 rpm.  
Subsequently, the 2.5fold mass of the mass of dried lipid film (71 l) of the same 
triethylenetetramine (TETA) solution was added and subjected to another DAC run 
for 5 min at 3540 rpm.  
In the last (third) centrifugation step, the 2.5fold mass of the mass of dried lipid film 
(71 l) of the PBS buffer (without TETA) was added and centrifugated for 5 min at 
3540 rpm again. 
Tab. 3. Parameters of DAC procedure 
1st Run of DAC 43 µl of Buffer solution with TETA 
2nd Run of DAC 71 µl of Buffer solution with TETA 
3rd Run of DAC 71 µl of PBS 
 
The resulting liposomal dispersion was diluted (filled up) with PBS buffer to obtain 
400 l of the final dispersion. 
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7.3.3 Purification of liposomal dispersion 
Separation of the free triethylenetetramine and the liposome-encapsulated TETA was 
achieved with the size exclusion chromatography (SEC).  
The small amount of Sephadex™ G-50 Fine was mixed with PBS and kept to swell 
for 10 minutes. The column was filled with this mixture and polyethylene membrane 
filters were placed at the both ends of the column. The column was flushed with 15 ml 
of PBS after every using. 
The liposomal dispersion with TETA was gently added to the column followed by 
PBS flow. The movement of this dispersion was possible to watch visually thanks to 
its white colouring. The middle of eluate, containing only liposomal TETA, was 
collected in the eppendorf tube as illustrated in Fig. 1 and stored in the refrigerator at 
2- 8° C. 
I used two different methods for the purification of liposomes: a one column method, 
and a two columns method.  
In the one column method (called purification 1 in this thesis), I prepared 400 µl of 
the liposomal dispersion and then I purified 60 µl of this dispersion at day 1 using the 
size exclusion chromatography (SEC). The same procedure, I repeated at time 2, 3, 4, 
5, and 8 day. 
In the two columns method (called purification 2 in this thesis), I prepared 400 µl of 
the liposomal dispersion and then I purified 360 µl of this dispersion at day 1 using the 
SEC. 60 µl of this purified dispersion was taken and purified at time 2, 3, 4, 5, and 8 
day. 
  
Fig. 13. The eluate of liposomes with TETA and without TETA 
I repeated this procedure three times for each experimental run. For better orientation, 
I marked samples with codes, where S means sample (S1 – S3), PH means pH  
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(3 or 7), P means purification (P1 or P2). For example: S1PH3P1 means sample 1, 
pH3 and purification 1. 




















7.3.4 Evaluation of the size and the size distribution of liposomes 
Liposome dispersions after the SEC were analysed by photon correlation spectroscopy 
(PCS) with a Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, United 
Kingdom) using a 633 nm red laser.  
Samples were diluted in PBS prior to measurement in the ratio 1:1000. To determine 
the size and the size distribution of the liposomal dispersions in the PBS buffer, the 
automatic mode with temperature of 25° C was used and the average of three 
measurements was taken. 
The results were described as Z-average and polydispersity index (PdI) in Tab. 5-16. 
7.4 Methods used in evaluation of encapsulation efficiency 
7.4.1 High performance liquid chromatography (HPLC) 
The concentration of cholesterol before the SEC, cholesterol after the SEC and TETA 
after the SEC were quantitatively analysed using HPLC ((Ultimate 3000, Dionex) with 




The relationships between absorbance and the concentration (calibration curves) were 
linear over the concentration range of 1-500 µM for TETA and 0.01- 5000 µM for 
cholesterol, in both cases with a correlation coefficient of 0.99 or better and an 
intercept value not statistically different from zero. The lower limit of qualification for 
TETA was 1 µM, for cholesterol 0.01 µM .The upper limit of qualification was 500 
µM in case of TETA and 5000 µM for cholesterol. 
7.4.1.1 Determination of cholesterol concentration in liposomes  
The separation was performed in Reversed-Phase-18 (Acclaim® 120, c18, 5µm, 120 
Å, 4.6 x 250 mm, Dionex) at 45° C and the peak was detected at 205 nm. The retention 
time was approximately 10.5 min and overall runtime was 16. Methanol and water, 
each of them with 0.05 % trifluoroacetic acid, were used as mobile phases with 
isocratic elution and the flow rate was 2ml/min. 
In order to detect the cholesterol concentration in liposomes, the liposomes must first 
be destroyed. This was achieved by dilution with methanol. For estimation of the chol 
concentration before the SEC, the original liposomal dispersion was diluted in ratio 
1:100 to achieve the total volume of 500 µl. 
To estimate concentration after the SEC, the dispersion of the cleaned liposomes was 
diluted 1:10 to the total volume of 500 µl again. This procedure was repeated at each 
out of the days according to the methods of purification mentioned above in the Section 
6.3.3. The amount of cholesterol in every sample was determined. 
I took 100 µl of this diluted dispersion and placed it into the HPLC glass vials three 
times. Before the beginning of chromatography, the samples were heated at 35° C and 
an aliquot of 50 µl of each sample solution was directly injected into the HPLC system. 
The average of 3 measurements was taken, Tab. 17–20. The detected concentrations 
of cholesterol before the SEC and after the SEC were used for the estimation of the 





Fig. 14. An example of a typical chromatogram of cholesterol 
7.4.1.2 Determination of TETA concentration in liposomes  
The chromatographic separation of TETA was achieved using a Luna 3μ C18 150 × 
3.0-mm reversed phase column (Phenomenex, Auckland) maintained at 25°C with a 
linear gradient mobile phase. Acetonitrile (ACN, mobile phase A) and water (mobile 
phase C), again each with 0.05 % trifluoroacetic acid, were used. The linear gradient 
program was: 0 min, 50 % A; 7 min, 70 % A; 7.5 min, 80 % A; 17.0 min, 80 % A; 
19 min, 95 % A; 23 min, 95 % A; 25 min, 50 % A; 35 min, 50 % A. Overall runtime 
was 36 minutes with the flow rate being maintained at 0.5 mL/min. The retention time 
of TETA was approximately 25.5 min and the peak was detected at 295 nm. 
The samples were treated as follows: to 45 µl of borax buffer in an eppendorf tube, 5 
µl of the liposomal dispersion with TETA and 450 µl of the FMOC solution in ACN 
(50 mmol/) were added. The samples were shaken for 30 minutes to complete 
derivatization reaction. After shaking, I took 100 µl three times and placed it into the 
HPLC glass vials. 
 
Fig. 15. An example of typical chromatogram of TETA 
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Again, the amount of TETA in the sample is proportional to the area under the peak. 
The detected concentrations were used for the estimation of the encapsulation 
efficiency of TETA in the liposomes. 
7.4.2 Estimation of the encapsulation efficiency of TETA in 
liposomes 
From the detected concentrations mentioned above, I calculated the ratio of TETA/ 
cholesterol before the SEC and the ratio of TETA/cholesterol after the SEC at each 
day of purification. The encapsulation efficiency (loading) of TETA in liposomes at 
day 1, 2, 3, 4, 5 and 8 was determined as the percentage ratio of the ratio TETA 
encapsulated in liposomes before the size exclusion chromatography and the ratio 
TETA encapsulated in liposomes after the SEC. 
The encapsulation efficiency (EE) was calculated with the following formula: 
 
𝐸𝐸 (%) =
𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑇𝐸𝑇𝐴 𝑖𝑛 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠 𝑎𝑓𝑡𝑒𝑟 𝑆𝐸𝐶
𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑇𝐸𝑇𝐴 𝑖𝑛 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝑆𝐸𝐶
· 100   (2) 
 






· 𝑒            (3) 
 
Where: C = theoretical (calculated) concentration of TETA expected in liposomes 
(mmol/l) 
a = the volume of TETA solution used in the first run by DAC (µl) 
b = the volume of TETA solution used in the second run by DAC (µl) 
d = the total volume of the original liposomal dispersion (µl) 





8.1 The measured values of liposome size and polydispersity 
All liposomal formulation I prepared for each experiment 3 times. Each sample was 
measured by PCS to verify the size and polydispersity of the liposomes after the SEC. 
During a single measuring each sample was measured 3 x 10 times. The results in 
Tables are expressed as a Z-average diameter d (nm) and a mean (n = 30) with standard 
deviation SD. The same way, polydispersity index PdI was estimated. The mean for 










d (nm) Mean (nm) SD   Mean SD 
1 
Day1 
151.7     0.116     
2 158.5 155.3 3.412 0.181 0.16 0.038 
3 155.6     0.182     
4 
Day2 
146.5     0.109     
5 144.5 145.1 1.250 0.133 0.13 0.025 
6 144.2     0.159     
7 
Day3 
170.6     0.189     
8 163.3 163.7 6.709 0.179 0.19 0.011 
9 157.2     0.200     
10 
Day4 
146.0     0.169     
11 142.2 143.1 2.610 0.135 0.14 0.023 
12 141.0     0.124     
13 
Day5 
147.3     0.162     
14 140.7 142.1 4.620 0.159 0.15 0.012 
15 138.4     0.140     
16 
Day8 
138.2     0.141     
17 136.8 137.2 0.839 0.149 0.15 0.004 











d (nm) Mean (nm) SD   Mean SD 
1 
Day1 
141.7     0.113    
2 138.2 139.4 1.966 0.145 0.14 0.020 
3 138.4     0.149     
4 
Day2 
142.8     0.130     
5 136.5 138.4 3.790 0.120 0.13 0.012 
6 136.0     0.143     
7 
Day3 
140.3     0.162     
8 135.6 136.4 3.568 0.170 0.16 0.006 
9 133.3     0.159     
10 
Day4 
144.2     0.170     
11 139.1 140.3 3.460 0.163 0.17 0.004 
12 137.6     0.164     
13 
Day5 
136.6     0.136     
14 136.0 135.1 2.100 0.140 0.13 0.008 
15 132.7     0.125     
16 
Day8 
136.7     0.122     
17 133.6 135.0 1.572 0.153 0.13 0.017 











d (nm) Mean (nm) SD   Mean SD 
1 
Day1 
151.2     0.169   
2 149.4 148.7 2.914 0.142 0.16 0.018 





0.160   
5 147.9 0.168 0.17 0.011 
6 143.6 0.182   
7 
Day3 
145.3     0.147   
8 142.9 142.6 2.810 0.135 0.15 0.018 





0.163   
11 139.5 0.151 0.17 0.017 
12 141.4 0.185   
13 
Day5 
138.9     0.145   
14 136.8 137.2 1.582 0.161 0.16 0.011 





0.135   
17 143.0 0.153 0.16 0.023 
















0.16 0.031 2 150.5 0.14 





0.15   
5 147.7 0.16 0.15  0.018  






0.14 0.011 8 148.9 0.13 






0.13 0.009 11 150.9 0.12 






0.14 0.004 14 148.4 0.14 






0.14 0.016 17 144.8 0.16 

















0.19 0.032 2 185.4 0.22 






0.20 0.028 5 172.2 0.18 






0.19 0.018 8 171.4 0.17 






0.18 0.013 11 170.3 0.20 






0.25 0.056 14 170.5 0.19 






0.18 0.021 17 161.4 0.19 

















0.11 0.019 2 168.9 0.10 






0.13 0.024 5 163.5 0.15 






0.13 0.010 8 166.5 0.14 






0.14 0.009 11 164.2 0.14 






0.14 0.005 14 162.2 0.14 






0.13 0.025 17 155.1 0.16 

















0.16 0.014 2 148.5 0.15 






0.16 0.013 5 149.7 0.17 






0.14 0.013 8 149.3 0.12 






0.14 0.012 11 152.6 0.14 






0.15 0.019 14 147.9 0.13 






0.17 0.031 17 161.5 0.15 

















0.16 0.006 2 142.5 0.17 






0.16 0.014 5 141.3 0.17 






0.16 0.005 8 138.7 0.16 






0.15 0.018 11 138.9 0.17 






0.15 0.014 14 148.3 0.15 






0.15 0.008 17 137.0 0.16 

















0.21 0.068 2 139.6 0.17 






0.15 0.010 5 138.7 0.16 






0.16 0.015 8 138.8 0.14 






0.14 0.010 11 142.8 0.15 






0.14 0.004 14 135.4 0.14 







17 136.0 0.14 

















0.17 0.021 2 150.3 0.18 






0.24 0.098 5 154.1 0.20 






0.33 0.048 8 269.7 0.30 






0.20 0.007 11 146.2 0.20 






0.11 0.110 14 164.0 0.23 







17 165.4 0.20 

















0.19 0.006 2 138.6 0.19 






0.19 0.043 5 137.6 0.16 






0.29 0.027 8 158.6 0.30 






0.18 0.030 11 140.1 0.16 





0.15   
14 135.1 0.15 0.16  0.015  







17 151.2 0.20 

















0.18 0.009 2 143.0 0.18 






0.22 0.018 5 159.1 0.20 






0.29 0.010 8 164.5 0.29 






0.21 0.048 11 149.0 0.27 






0.19 0.008 14 145.0 0.20 







17 154.8 0.31 






Fig. 16. The influence of storage time (days) and pH value on the particle size d (mm) for 
liposomes purified by the one column method (P1) 
 
 
Fig. 17. The influence of storage time (days) and pH value on the particle size d (mm) for 






























8.2 Estimation of encapsulation efficiency of TETA in 
liposomes 
Tab. 17. Results of EE (%) for S1-S3PH3P1 
PH3P1 


























712. 500 50. 667 1406.250 
2. 110 2.111 99. 964 7.11 
2 2.314 2.178 106.250 7.56 
3 1.569 1.917 81.854 5.82 
4 2.273 2.285 99.462 7.07 
5 2.446 2.149 113.807 8.09 
8 1.889 2.228 84.755 6.03 
S2 
1 
712.500 45. 363 1570.652 
1.687 2.239 75.355 4.80 
2 1.655 2.307 71.721 4.57 
3 1.936 2.612 74.130 4.72 
4 2.124 2.766 76.794 4.89 
5 1.597 2.046 78.060 4.97 
8 1.563 2.073 75.396 4.80 
S3 
1 
712.500 46.427 1534.678 
2.133 1.762 121.036 7.89 
2 2.257 2.241 100.690 6.56 
3 2.228 2.118 105.230 6.86 
4 2.794 2.604 107.297 7.00 
5 1.808 1.799 100.515 6.55 





Tab. 18. Results of EE (%) for S1-3PH3P2 
PH3P2 

























712.500 39.877 1786.759 
6.697 7.465 89.712 5.20 
2 3.465 0.429 808.404 45.24 
3 3.679 0.585 628.456 35.17 
4 3.362 0.485 693.109 38.79 
5 3.739 0.545 686.420 38.42 
8 3.671 0.523 702.339 39.31 
S2 
1 
712. 500 35.287 2019.176 
5.863 5.131 114.260 5.66 
2 3.711 0.426 871.086 43.14 
3 3.723 0.474 785.512 38.90 
4 3.618 0.431 839.773 41.59 
5 3.705 0.343 1080.106 53.49 
8 3.564 0.369 965.039 47.79 
S3 
1 
712.500 36.003 1978.983 
8.949 6.554 136.534 6.90 
2 4.616 0.477 967.641 48.90 
3 4.702 0.604 778.840 39.36 
4 4.233 0.530 798.089 40.33 
5 4.254 0.528 805.178 40.69 





Tab. 19. Results of EE (%) for S1-3PH7P1 
PH7P1 

























712. 500 47.807 1490.378 
1.789 1.392 128.577 8.63 
2 1.670 1.392 119.985 8.05 
3 1.627 1.881 86.477 5.80 
4 1.953 1.970 99.120 6.65 
5 4.703 2.334 201.511 13.52 
8 0.729 1.458 50.004 3.36 
S2 
1 
712. 500 46.123 1544.771 
1.537 2.435 63.116 4.09 
2 1.616 2.435 66.345 4.29 
3 1.444 1.551 93.127 6.03 
4 4.044 2.540 159.221 10.31 
5 3.810 2.135 178.465 11.55 
8 1.165 1.755 66.389 4.30 
S3 
1 
712. 500 47.687 1494.128 
1.667 1.888 88.310 5.91 
2 1.710 1.888 90.562 6.06 
3 2.369 2.085 113.602 7.60 
4 4.457 2.271 196.270 13.14 
5 4.753 2.22 214.138 14.33 





Tab. 20. Results of EE (%) for S1-3PH7P2 
PH7P2 

























712. 500 54.347 1311.028 
5.833 9.440 61.788 4.71 
2 4.546 0.978 464.984 35.47 
3 4.519 0.960 470.766 35.91 
4 5.000 0.862 579.792 44.22 
5 6.088 0.769 792.078 60.42 
8 7.213 1.128 639.223 48.76 
S2 
1 
712. 500 37.110 1919.968 
10.034 9.914 101.209 5.27 
2 4.263 0.903 471.969 24.58 
3 4.861 0.901 539.711 24.58 
4 4.910 0.742 661.733 34.47 
5 6.858 0.531 1291.527 67.27 
8 5.616 0.608 923.192 48.08 
S3 
1 
712. 500 41.680 1709.453 
11.037 9.378 117.696 6.89 
2 4.412 0.963 458.165 26.80 
3 4.567 0.923 494.977 28.96 
4 4.327 0.716 603.982 35.33 
5 5.823 0.546 1066.566 62.39 

















































































The blood brain-barrier represents the main obstacle for the treatment of central 
nervous system diseases. One possibility how to deliver drugs into the brain is the use 
of colloidal carrier systems—amongst others, the liposomes.45 Liposomes are 
commonly prepared for intravenous administration in the pharmaceutical industry. 
The parenteral administration route is the most effective and common form of delivery 
for active drug substances with poor bio-availability. This route maintains its value 
due to special advantages like fast onset of action, targeting of the drug to the desired 
site of action, prevention of the first pass metabolism etc.46  
Triethylenetetramine (TETA) is a drug used for the treatment of Wilson's disease as 
was described in section 6.5 and it is poorly absorbed, with relatively low 
bioavailability. The aim of this thesis was to prepare liposomes loaded with TETA 
dissolved at pH3 or/and pH7 by the film method with subsequent dual asymmetric 
centrifugation and to investigate their size and their size distribution by photon 
correlation spectroscopy and to estimate the encapsulation efficiency at day 1, 2, 3, 4, 
5 and 8. 
Liposomes were prepared using the film hydration method combined with dual 
asymmetric centrifugation (DAC). The formulations subjected to DAC usually need 
to contain a high amount of phospholipids to obtain a sufficient viscosity. Egg-
phospatidylcholine, cholesterol and PEG - 2000- PE in ratio 55:40:5 were used to 
prepare the liposomes.  
In this work, two different pH values were used to study the influence of pH value on 
the liposome stability and the encapsulation efficiency of TETA. The values were 
chosen based on preliminary studies in the laboratory that indicated the sufficient 
stability of liposomes (the average size and the polydispersity). 
9.1 Liposome size and polydispersity 
The average size (described as Z-average in this thesis) and the size distribution of 
liposomes (described as polydispersity index, PdI, in this thesis) are important 
parameters that impact on the physical properties and biological fate of the liposomes 
and their entrapped substances. These parameters affect the physical stability, in vivo 
distribution and the size uniformity of the liposomal formulation as was described in 
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the theoretical section 6.1.1. The PEG-covered i.e. sterically shielded liposomes, avoid 
the mononuclear phagocytic system, however, this is directly associated with the size 
of liposomes. The best results are achieved if the liposome size is between 70 and 200 
nm.47 
The polydispersity index describes the distribution width of the particle size and is 
indexed from 0 to 1. The polydispersity index of 0 corresponds to a completely 
homogenous monodisperse sample, whereas the polydispersity index of 1 indicates a 
very broad size distribution. Usually, a sample with the polydispersity index <0.20 is 
considered to be monodisperse. A higher value of PdI normally indicates multiple sizes 
of particles in the given formulation.47 The slow settling could occur for the large 
particles or aggregates under such circumstance. 
In this work, the influence of the time of storage at days 1, 2, 3, 4, 5 and 8 after the 
preparation on the size and size distribution of the liposomal formulation of TETA was 
investigated using photon correlation spectroscopy (PCS). Obtained data are presented 
in Tables 5–16. 
The Figures 17 and 18 summarize the influence of storage (days) and the pH value 
used for dissolution of TETA on the particle size (nm) for liposomes purified by the 
one column method (P1) and by the two columns method (P2). As we can see in Figure 
18, the average size of particles complied with the stated limit of 200 nm for all the 
time except for pH7 at day 3 when it was above this limit. This probably resulted from 
the high variability of the experimental data as could be seen by the comparison of 
results in Tables 14–16. The larger size of liposomes detected for the only one sample 
(Table 14) could indicate the experimental error. If we calculate the average size for 
pH7 day 3 using the data from Tables 15 and 16, the size of liposomes is 174.2 nm. 
The results verify good stability of liposomes. This could also be seen from Figures 
17 and 18 for 8 days at both pH values used. The influence of the method of 
purification on the size of liposomes was not observed. However, the higher 
polydispersity was detected for pH7P2, which is ineligible for liposome preparation. 
The results displayed in Tables 5–13 indicates that the liposomes formulations could 
be assumed monodisperse. 
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9.2  Encapsulation efficiency 
The encapsulation efficiency (EE) of a drug into a nanoparticulate drug delivery 
system is one out of the most important dependent variables. For the estimation of EE, 
it was necessary to determine the concentration of cholesterol and TETA before the 
size exclusion chromatography (SEC) as well as the concentration of cholesterol and 
TETA after the SEC. The concentration of TETA before the SEC was calculated using 
the equation 3 and it was always equal to 712.5 mmol/l. The concentration of TETA 
after the SEC was estimated using the method described in Sections 6.5.1 and 7.4.1.2. 
The HPLC method was used. 
For the detection of cholesterol concentration before and after the SEC, it is necessary 
to destroy the liposomes. This was achieved by dilution of liposomal dispersion with 
methanol. The concentration of cholesterol differed depending on how much of 
cholesterol had built in liposomes during their preparation.  
The encapsulation efficiency was then calculated as the ratio of the TETA/cholesterol 
ratios before the SEC and after the SEC in accordance to the equation 2. The results 
of the EE estimation are summarized in the last column of Tables 17–20. The influence 
of the method of purification and the pH value can be observed in Figures 18–21. 
The significant influence of the method of purification on EE was found as illustrated 
in Figures 18 and 19. The purification by the two columns method (P2) was found to 
give higher encapsulation yield than the purification by one column method (P1). The 
values of EE for P1 in a range of 4 % to 14 % were observed, however, the EE from 
24 % to 67 % was detected for P2. The lower EE values from from 4 % to 8 % for P2 
referred to the first day in Table 18 and 20 are associated with the method of 
purification as described in the experimental section. At the first day, TETA and 
cholesterol concentration in liposomal formulation were determinated only by just 
once purification as in the procedure signed with P1. 
For the one column method, the encapsulation efficiency of TETA-liposomes with 
pH3 did not revealed any significant changes during days of storage (Fig. 20). On the 
other side, the EE for pH7 showed increasing tendency reaching the maximum value 
of about 13.13 % at day 5. 
Generally, the higher EE was obtained for the two columns method of purification. As 
can be seen in Figure 21, the highest encapsulation efficiency for pH3 was found at 
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day 2 (45.76 %) in comparison to pH7 when the highest EE was found at day 5  
(63.36 %). 
In a summary, the consistent values of the encapsulation efficiency during the days of 
storage were observed with the dissolution of TETA at pH3 value for both methods of 
purification. In contrast, the higher variability of resulting data were revealed 





From the results of this thesis the following conclusions can be summarized: 
 It was possible to prepare liposomes with encapsulated TETA by a film hydration 
method followed by dual asymmetric centrifugation. The average liposome size 
was below 200 nm. 
 Liposomes containing TETA dissolved at pH3 or/and pH7, respectively, were 
stable for 8 days when they were stored in the refrigerator at 2–8° C. No effect of 
pH on the stability was observed. However, the size of liposomes was slowly 
decreasing with the time of storage. 
 The method of purification did not influence the stability of liposomes; the average 
size remained unchanged for eight days of storage. However, the method of 
purification influenced the polydispersity. The higher polydispersity was observed 
for liposomes containing TETA dissolved at pH7 and purified by the two columns 
method. 
 It is possible to successfully express the encapsulation efficiency based on the 
estimation of the concentration of TETA and the concentration of cholesterol 
before the size exclusion chromatography and after the size exclusion 
chromatography. The encapsulation efficiency was slightly influenced by the value 
of pH used and significantly influenced by the method of purification: 
- For the one column method, the values of the encapsulation efficiency 
ranged from 5 % to 14 % depending on the pH value. The higher 
encapsulation efficiency was observed at pH7 in comparison to pH3, but the 
variability of the results was high. 
- For the two columns method, the encapsulation efficiency around 67 % at 
pH7 was observed; however the values of the encapsulation efficiency varied 
in the large range from 25 % to 67 %. 
- For the two columns method, the more consistent results of the encapsulation 
efficiency at pH3 were observed—ranging from 35 % to 54 %. 
 Obtained results should set out an efficient direction for further development of 
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